Bone Biologics Corporation (BBLG)

$0.2814

+0.00 (+0.50%)
Rating:
Recommendation:
-
Symbol BBLG
Price $0.2814
Beta 0.176
Volume Avg. 0.22M
Market Cap 4.306M
Shares () -
52 Week Range 0.25-6.78
1y Target Est -
DCF Unlevered BBLG DCF ->
DCF Levered BBLG LDCF ->
ROE -63.76% Strong Sell
ROA -49.14% Strong Sell
Operating Margin -
Debt / Equity 18.16% Neutral
P/E -1.55 Sell
P/B 0.66 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BBLG news


Healthcare
Medical Devices
NASDAQ Capital Market

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.